NFE2L2 and cancer: Despite the chemopreventive action of NRF2, growing evidence suggests that mutations in KEAP1 and/or NRF2 cause the aberrant activation of NRF2, which leads to oncogenesis and drug resistance in cancer cells [11, 12].